<DOC>
	<DOCNO>NCT02967211</DOCNO>
	<brief_summary>Primary Objective : To demonstrate noninferiority Toujeo versus `` standard care '' basal insulin therapy measure glycated hemoglobin ( HbA1c ) change Secondary Objectives : - To demonstrate superiority Toujeo versus `` standard care '' basal insulin non-inferiority criterion meet , measure HbA1c change . - To compare Toujeo `` standard care '' basal insulin term patient persistence assign basal insulin therapy without intensification . - Risk hypoglycemia include document , symptomatic hypoglycemia ( ≤70 mg/dL ) severe ( accord ADA Working Group ) . - Change fast plasma glucose ( FPG ) . - Change body weight . - Differences patient report outcomes measure Diabetes Treatment Satisfaction Questionnaire Status Change version ( DTSQs DTSQc ) . - Change hypoglycemic control subscale ( HCS ) . - Healthcare resource utilization include hospitalization emergency department health care provider visit healthcare cost .</brief_summary>
	<brief_title>A `` Real World '' Trial Determine Efficacy Health Outcomes Toujeo Compared `` Standard Care '' Basal Insulin Patients Already Using Basal Insulin</brief_title>
	<detailed_description>The total study duration 55 week , consist 1 week screen period site , 26 week treatment period , 26 week extension period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes insufficiently control ( HbA1c &gt; 7 % ) current ( ≥6 month ) `` standard care '' basal insulin therapy ( include insulin glargine U100 , Levemir , NPH , Tresiba ) without oral agent ( metformin , sulfonylurea , thiazolidinedione , DPP4 inhibitor , SGLT2 inhibitor , glinides , α glucosidase inhibitor ) without use GLP1 receptor agonist . Fasting plasma glucose ( FPG ) &gt; 130 mg/dL ( 7.2 mmol/L ) . Adult patient sign Informed Consent Form ( ICF ) privacy form ( ) . Exclusion criterion : HbA1c ≤7 % , upper bound . Age &lt; 18 year . Type 1 diabetes mellitus . Any clinically significant abnormality identify physical examination , laboratory test , vital sign time screen , major systemic disease result short life expectancy opinion Investigator would restrict limit patient 's successful participation duration study . Use product contain short rapid act insulin since time diagnosis type 2 diabetes mellitus temporary use pregnancy hospitalization . Use product contain short rapid act insulin occur within 3 month prior time screen . Use oral hypoglycemic agent note inclusion criterion , GLP1 receptor agonist approve use insulin , investigational agent ( drug , biologic , device ) within 3 month prior time screen . All contraindication `` standard care '' insulin therapy warnings/precautions use display respective National Product labeling product . Hypersensitivity insulin glargine Toujeo excipients . Pregnancy lactation . Women childbearing potential effective contraceptive method . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>